Funding profile · Healthcare IT, clinical trial recruitment

HealthKey

A pre-seed, Y Combinator backed company with one SEC filing on record: a $484,833 SPV that closed in December 2024, weeks before its public launch. Here is what that filing shows, and where its issuer name is not the company name.

$484,833Sold in the HealthKey Pre Seed I SPV, Form D filed Jan 6, 2025
32Investors in the SPV, about $15,151 average
$500KTotal funding, aggregator-reported (PitchBook, VCBacked)

Data as of September 25, 2026. Company-reported and aggregator-reported figures are labeled.

Rounds at a glance

When Round Amount Investors Source
Winter 2025 Y Combinator, W25 batch Not disclosed Y Combinator YC data
Dec 2024, filed Jan 2025 Pre-seed SPV: “HealthKey Pre Seed I Oct 2024, a Series of CGF2021 LLC” $484,833 of $484,833 offered 32 investors; administered by Sydecar Form D
As reported Total funding to date $500K approximate Not named beyond the SPV Aggregator

What the filings show

HealthKey Pre Seed I Oct 2024, a Series of CGF2021 LLC · Form D · filed Jan 6, 2025

First sale
Dec 21, 2024
Type
Pooled investment fund (single-company SPV)
Offered
$484,833
Sold
$484,833 · $0 remaining
Investors
32 · average about $15,151
Exemptions
Rule 506(b); Investment Company Act Section 3(c)(1)
Related persons
Sydecar LLC (administrator, director); Brett Sagan (executive officer, general manager of Sydecar LLC)
Filing
SEC EDGAR, CIK 0002050618

Reading the filings

  1. The vehicle closed before the launch.First sale was Dec 21, 2024, about seven weeks before HealthKey’s public Y Combinator launch post in February 2025. The pre-seed money was in hand before the company went public with its product.
  2. Small checks, wide base.$484,833 came from 32 investors, about $15,151 each. That pattern, many similarly sized checks with no lead named in the filing, reads as an angel or syndicate round rather than a single institutional lead.
  3. The filer name is not the company name.The Form D issuer of record is “HealthKey Pre Seed I Oct 2024, a Series of CGF2021 LLC,” a Sydecar-administered special purpose vehicle, not “HealthKey, Inc.” An EDGAR company-name search for “healthkey” returns only this one filer. Companies that raise entirely through an SPV or under Section 4(a)(2) instead of Regulation D can show no Form D at all under their own name, so the gap does not by itself mean no other money moved.
  4. Announced and aggregator totals are close to the filed amount.PitchBook and VCBacked separately put HealthKey’s total funding at about $500,000, close to the $484,833 shown in the SPV filing. That suggests the SPV may account for most or all of the outside capital raised to date, though neither aggregator cites a primary source beyond general company data.
  5. The founding year does not match across sources.PitchBook’s profile for the Austin, TX HealthKey lists 2023 as the year founded, while Y Combinator’s company page and HealthKey itself give 2025, consistent with its Winter 2025 YC batch. No later filing or announcement resolves the difference.
  6. No second Form D has appeared.As of this page, no additional Form D, amendment, or new SPV naming HealthKey has been filed since January 2025, despite a growing list of company-published customer deployments through 2025 and 2026.

Commercial signals

Signal Detail Source type
Product review The Rundown AI, an independent AI tools reviewer, confirmed HealthKey as an active EHR-connected prescreening platform as of Aug 31, 2026, and noted it should not be confused with an unrelated London company using the same name. Independent
Named site customers Flourish Research, Access CCT, Tekton Research, US Urology Partners, Oregon Urology Institute and Urology Centers of Alabama, each named in HealthKey’s own case studies with a specific sponsor trial. Company-stated
Sponsor trials referenced Case studies name trials for Alnylam, Eli Lilly, UCB, Johnson & Johnson, CG Oncology, Merck, Novartis and Valencia. None of these sponsors were found independently confirming the HealthKey relationship. Company-stated
Pricing Homepage advertised $0 upfront, free implementation and a success-fee model through an offer stated as valid through Jul 31, 2026. Current terms require a quote. Company-stated
Team size 10, per Y Combinator’s company page, 2025. YC data

What to watch

  • A Form D filed under HealthKey’s own corporate name, which would indicate an institutionally led round.
  • A named lead investor. None appears in the SPV filing or in aggregator profiles.
  • Independent confirmation from any of the named customers or sponsors.
  • Resolution of the 2023 versus 2025 founding-year discrepancy between PitchBook and the company.

The HealthKey story on Healthcare DiscoveryHealthcare Discovery

Related companies

Sources

  1. Public recordForm D, HealthKey Pre Seed I Oct 2024, a Series of CGF2021 LLC, CIK 0002050618SEC EDGAR · filed Jan 6, 2025
  2. Public recordEDGAR company filing history for HealthKey Pre Seed I Oct 2024, a Series of CGF2021 LLCSEC EDGAR · accessed Sep 25, 2026
  3. Public recordForm D filing summary, HealthKey Pre Seed I Oct 2024, a Series of CGF2021 LLCformds.com · Jan 6, 2025
  4. Public recordForm D filing detail, HealthKey Pre Seed I Oct 2024, a Series of CGF2021 LLC13f.info · Jan 6, 2025
  5. IndependentHealthKey (Medical Records Systems) company profilePitchBook · accessed Sep 25, 2026
  6. IndependentHealthKey Funding & Investors, AustinVCBacked · Mar 12, 2025
  7. IndependentHealthKey Review: Clinical Trial AI & PricingThe Rundown AI · Aug 31, 2026
  8. IndependentHealthKey: AI-powered Patient Identification for Clinical Trials, company pageY Combinator · Feb 2025
  9. CompanyHealthKey homepagegethealthkey.com · accessed Sep 25, 2026
  10. CompanyHealthKey customer case studiesgethealthkey.com/blog · accessed Sep 25, 2026

Compiled from SEC and other public records and published reports as of September 25, 2026. Form D notices report offerings under Regulation D; amounts reflect the filing date. Healthcare Venture Capital Fund holds no position in HealthKey. This page is not an offer to sell or a recommendation to buy any security.